BioAsia, the prestigious healthcare and Life Sciences event organized by the Government of Telangana, is gearing up for its 21st edition in Hyderabad. The Minister for Information Technology, Industries & Commerce, Sri Duddilla Sridhar Babu, conducted a comprehensive review of the preparations for this global conference scheduled to be held from February 26 to 28, 2024, at the Hyderabad International Convention Center (HICC).
The 21st edition of BioAsia will convene government dignitaries, industry leaders, researchers, entrepreneurs, and other delegates under the theme “Data & AI: Redefining Possibilities.” With an impressive lineup of over 70 influential speakers, including global CEOs and industry leaders, the event is expected to attract over 3000 participants.
Keynote speakers for the event include Mr. David Ricks (CEO, Eli Lilly and Company), Dr. Christopher Boerner (Incoming CEO, Bristol Myers Squibb), Mr. Geoff Martha (Chairman and CEO, Medtronic), and Prof. Gregg Semenza (Nobel Laureate & Professor at Johns Hopkins School of Medicine), among others.
The event aims to be a dynamic platform for networking and collaboration, featuring an increased exhibition with over 200 companies showcasing groundbreaking advancements and cutting-edge products. BioAsia 2024 will provide a global stage for promising startups in the pharmaceutical, biotech, life sciences, health-tech, and med-tech sectors.
Mr. Sridhar Babu expressed his enthusiasm for BioAsia’s growing global stature, stating, “BioAsia has emerged as a critical instrument for the development of the Indian and global Life-Sciences and allied industries over the last two decades.”
Mr. Jayesh Ranjan, IAS, Principal Secretary, Industries & Commerce Dept., Government of Telangana, highlighted BioAsia’s role in sparking renewed emphasis on the life-sciences industry over the past 20 editions.
Mr. Shakthi Nagappan, Director of Life Sciences, Govt. of Telangana, and CEO of BioAsia, anticipates the 21st edition to be a milestone event, bridging gaps in the healthcare industry and fostering innovation.
With EY as the knowledge partner, BioAsia 2024 will focus on themes such as Transformative Innovation, India’s Bid for Global R&D Dominance, Leading the Health-tech Revolution, and more, addressing pertinent industry issues.
About BioAsia: BioAsia is a dynamic global platform that brings together key stakeholders in the biotechnology industry, fostering collaborations, driving growth, and advocating for the transformation from illness to wellness on a global scale. The 21st edition aims to continue its legacy of driving innovation, knowledge sharing, and shaping the future of biotechnology.
